Larotrectinib

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
LOXO-101, ARRY-470
API & Intermediates
KAPI2F12
1223403-58-4
MFCD28902192
46188928
20255616
image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Larotrectinib
C21H22F2N6O2
428.44
≥98% (HPLC)
Yellow to Pale-yellow Solid
240-243°C
5g,10g,25g,50g,100g,250g and 500g
Store at -20°C temp.
Larotrectinib (also named as LOXO-101, ARRY-470) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRKA,TRKB and TRKC) family receptors. It is specifically developed for the treatment of TRK-Fusion cancers.
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. [1]
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. [2]
References:
[1] B.Ricciuti, et al, Med. Oncol., 2017, 34(6), p 105.
[2] A.Drilon, et al, N. Engl. J. Med., 2018, 378(8), pp 731-739.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
RETCS
Legal Information
Warning
H315,H319,H335
P261,P305+P351+P338,P302+P352
2934990300
NONH for all modes of transport

Sales limitations may apply.
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.